CRISPR Therapeutics AG (CRSP) Current Deferred Revenue (2016 - 2026)
CRISPR Therapeutics AG (CRSP) posted Current Deferred Revenue of $15.3 million for Q1 2026, down 2.71% sequentially from $15.8 million in Q4 2025, and up 407.91% YoY from $3.0 million in Q1 2025.
CRISPR Therapeutics AG (CRSP) Current Deferred Revenue (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Current Deferred Revenue for 10 years, with the latest figure at $15.3 million in Q1 2026.
- Quarterly Current Deferred Revenue rose 407.91% year-over-year to $15.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.3 million (up 407.91% YoY) and the FY2025 annual result came in at $15.8 million, up 310.17% from the prior year.
- Current Deferred Revenue slipped to $15.3 million in Q1 2026 per CRSP's latest filing, from $15.8 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $15.8 million in Q4 2025 and troughed at $1.3 million in Q3 2025.
- A 4-year average of $6.4 million and a median of $4.1 million in 2024 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2025 and 2026: Current Deferred Revenue slumped 71.11% in 2025, then soared 407.91% in 2026.
- Over 4 years, Current Deferred Revenue stood at $12.3 million in 2023, then plunged by 68.74% to $3.8 million in 2024, then surged by 310.17% to $15.8 million in 2025, then dropped by 2.71% to $15.3 million in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $15.3 million, $15.8 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.19 Mn |
| Mar 31, 2026 | 15.34 Mn |
| Dec 31, 2025 | 15.77 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Mar 31, 2025 | 3.02 Mn |
| Dec 31, 2024 | 3.85 Mn |
| Sep 30, 2024 | 4.48 Mn |
| Jun 30, 2024 | 4.76 Mn |
| Mar 31, 2024 | 4.07 Mn |
| Dec 31, 2023 | 12.30 Mn |
| Sep 30, 2023 | 3.50 Mn |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 1.56 Mn |
| Jun 30, 2021 | 2.07 Mn |
| Mar 31, 2021 | 1.80 Mn |
| Dec 31, 2020 | 12.20 Mn |
| Sep 30, 2020 | 610,000.00 |
| Jun 30, 2020 | 759,000.00 |
| Mar 31, 2020 | 803,000.00 |